|
MANAGEMENT
Hatchtech's management team is a small but focused group that is
leveraged by use of a global network of drug development, crop
protection, veterinary, regulatory
and commercial contractors and advisors.
Hatchtech's management team are:
Dr Paul MacLeman
CHIEF EXECUTIVE OFFICER
Paul is a veterinary surgeon (BVSc,University
of Sydney) and has additional qualifications including an MBA (MGSM), Grad Dip Tech Mgt (Risk & Valuation),
Grad Cert in Eng (Process Design & Control), and is a Fellow of the AICD.
He is also past director of the Veterinary Manufacturers and Distributors
Association and a serving member of the Ausbiotech AgBiotech Advisory
Committee.
Paul's previous roles have included Chief
Operating Officer for Imugene Ltd where he was responsible for re-focussing the
company's commercialisation strategy & systems and evaluating
new opportunities. Prior to this Paul was Vice President of
Agenix Ltd, heading their global veterinary immunodiagnostics business and was
part of the senior leadership team. Here he gained experience in managing global
business units and on-market product portfolios. Paul also has experience in
founding life sciences start-ups and has worked in Investment Banking focusing
on the analysis and financing of technology companies.
Dr Vern Bowles:
CHIEF SCIENTIFIC OFFICER
Vern is the founder of Hatchtech and the research
underpinning the core intellectual property is the culmination of 15
years of his work. He has devoted a significant proportion of his
research career to studying the role of ectoparasite proteases in
parasite infections, parasite nutrition and immune evasion. This work
has been extended to the role of proteases in egg hatching in the sheep
blowfly, head lice and other pests. Vern is an integral part of
Hatchtech where he is responsible for the emerging crop, household and
veterinary programmes and is also playing an important role in the
back-up screening for new compounds for the head lice program. Vern is
also the Deputy Director of the Centre for Animal Biotechnology in Melbourne.
Dr Maria Dynon
REGULATORY AND CLINICAL MANAGER
Maria has over 25 years varied experience in the
pharmaceutical industry, including three years as a TGA preclinical
evaluator and over 11 years as a consultant to the biotech and
pharmaceutical industry with Kendle International Inc and its
forerunner, Synermedica. Maria also spent nine years at the
Therapeutic Goods Administration managing registration applications in
Australia, including twelve successful registration applications for
new chemical entities. Prior to this, Maria worked as a product
manager/group product manager for the multinational research-based
pharmaceutical company Farmitalia Carlo Erba (now part of Pfizer),
during which time the company launched four new chemical entities in
Australia.
Dr Lewis Schulz
CHIEF OPERATING OFFICER
Lewis has more than ten years first hand local and
international experience with drug and device development. This has
included the transfer of a new anti-inflammatory agent from the
laboratory to the clinic and in this role he was responsible for the
management of preclinical and clinical development activities. His
previous experience also includes roles focussed on chemistry,
manufacturing and regulatory affairs, and six years in European posts
with international pharmaceutical companies. While working for Bristol
Myers Squibb International, Lewis was instrumental in development and
implementation of regulatory and marketing strategy for their oncology
portfolio in the Central and Eastern European region.
|
